Cargando…

Everyday life experiences of spouses of patients who suffer from pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension

INTRODUCTION: Spouses play a crucial role, both physically and psychologically, for patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Our aim was to investigate the spouse's experiences when living with a partner diagnosed with PAH or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ivarsson, Bodil, Sjöberg, Trygve, Hesselstrand, Roger, Rådegran, Göran, Kjellström, Barbro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387993/ https://www.ncbi.nlm.nih.gov/pubmed/30815471 http://dx.doi.org/10.1183/23120541.00218-2018

Ejemplares similares

Health-related quality of life, treatment adherence and psychosocial support in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
por: Ivarsson, Bodil, et al.
Publicado: (2018)

Coping, social support and information in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A 2-year retrospective cohort study
por: Ivarsson, Bodil, et al.
Publicado: (2018)

Perceptions of Received Information, Social Support, and Coping in Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension
por: Ivarsson, Bodil, et al.
Publicado: (2014)

The Odyssey from Symptom to Diagnosis of Pulmonary Hypertension from the Patients and Spouses Perspective
por: Ivarsson, Bodil, et al.
Publicado: (2021)

Information Experiences and Needs in Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension
por: Ivarsson, Bodil, et al.
Publicado: (2014)

Outpatient specialist clinics for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the Nordic countries
por: Kjellström, Barbro, et al.
Publicado: (2020)

Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
por: Kjellström, Barbro, et al.
Publicado: (2020)

Underfilling decreases left ventricular function in pulmonary arterial hypertension
por: Sjögren, Hannah, et al.
Publicado: (2021)

Prevalence of potential drug–drug interactions with disease‐specific treatments in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A registry study
por: Norell, Puck N., et al.
Publicado: (2022)

Sex-specific differences and survival in patients with idiopathic pulmonary arterial hypertension 2008–2016
por: Kjellström, Barbro, et al.
Publicado: (2019)

Atrioventricular plane displacement and regional function to predict outcome in pulmonary arterial hypertension
por: Lindholm, Anthony, et al.
Publicado: (2022)

Longitudinal changes in risk status in pulmonary arterial hypertension
por: Bouzina, Habib, et al.
Publicado: (2020)

Predicting mortality during long-term follow-up in pulmonary arterial hypertension
por: Kylhammar, David, et al.
Publicado: (2021)

Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension
por: Kjellström, Barbro, et al.
Publicado: (2022)

Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy: a registry-based study
por: Hjalmarsson, Clara, et al.
Publicado: (2020)

Pulmonary arterial hypertension in systemic sclerosis—when criteria and pathobiology differ
por: Andréasson, Kristofer, et al.
Publicado: (2019)

Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension
por: Bouzina, Habib, et al.
Publicado: (2019)

Plasma matrix metalloproteinase 2 is associated with severity and mortality in pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2022)

Societal costs associated to chronic thromboembolic pulmonary hypertension: A study utilizing linked national registries
por: Kjellström, Barbro, et al.
Publicado: (2023)

Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment
por: Hjalmarsson, Clara, et al.
Publicado: (2021)

Plasma TRAIL and ANXA1 in diagnosis and prognostication of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2023)

Respiratory rate modulation improves symptoms in patients with pulmonary hypertension
por: Kjellström, Barbro, et al.
Publicado: (2021)

Societal costs associated with pulmonary arterial hypertension: A study utilizing linked national registries
por: Runheim, Hannes, et al.
Publicado: (2023)

Decreased biventricular longitudinal strain in patients with systemic sclerosis is mainly caused by pulmonary hypertension and not by systemic sclerosis per se
por: Lindholm, Anthony, et al.
Publicado: (2019)

Circulating plasma microRNAs in systemic sclerosis-associated pulmonary arterial hypertension
por: Wuttge, Dirk M, et al.
Publicado: (2021)

Increased right atrial volume measured with cardiac magnetic resonance is associated with worse clinical outcome in patients with pre‐capillary pulmonary hypertension
por: Bredfelt, Anna, et al.
Publicado: (2018)

Quality of life and functional status after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: A Swedish single‐center study
por: Kallonen, Janica, et al.
Publicado: (2023)

Risk assessment in pulmonary arterial hypertension: A step towards clinical implementation based on the 2022 ESC/ERS pulmonary hypertension guidelines
por: Ahmed, Abdulla, et al.
Publicado: (2023)

Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2019)

Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2021)

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Humbert, Marc, et al.
Publicado: (2019)

Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective
por: Koudstaal, Thomas, et al.
Publicado: (2020)

Cardiac Magnetic Resonance Imaging in Pulmonary Arterial Hypertension: Ready for Clinical Practice and Guidelines?
por: Kjellström, Barbro, et al.
Publicado: (2020)

Right atrial volume measured by cardiac magnetic resonance correlates with NT-ProBNP and invasive right atrial pressure in pulmonary hypertension, with and without systemic sclerosis
por: Gyllenhammar, Tom, et al.
Publicado: (2016)

Metabolic profile in endothelial cells of chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension
por: Smolders, V. F. E. D., et al.
Publicado: (2022)

Doppler estimates of pulmonary vascular resistance to phenotype pulmonary hypertension in heart failure
por: Venkateshvaran, Ashwin, et al.
Publicado: (2019)

Pulmonary artery dysfunction in chronic thromboembolic pulmonary hypertension
por: Chibana, Hidetoshi, et al.
Publicado: (2017)

CXCL13 in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Olsson, Karen M., et al.
Publicado: (2016)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022)

Plasma ADAMTS13 and von Willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension
por: Ahmed, Abdulla, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mi5ar803qfg5t60q1pftu25res